Prognostic Value of VEGF in Patients Submitted to Percutaneous Coronary Intervention

C. Ramos; Patrícia Napoleão; Mafalda Selas; Cláudia Freixo; Ana Maria Viegas-Crespo; Miguel Mota Carmo; Rui Cruz Ferreira; Teresa Pinheiro

doi:10.1155/2014/135357

Prognostic Value of VEGF in Patients Submitted to Percutaneous Coronary Intervention

C. Ramos, Patrícia Napoleão, Mafalda Selas, Cláudia Freixo, Ana Maria Viegas-Crespo, Miguel Mota Carmo, Rui Cruz Ferreira, Teresa Pinheiro

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

16 Downloads (Pure)

Abstract

We examined the longitudinal changes of VEGF levels after percutaneous coronary intervention for predicting major adverse cardiac events (MACE) in coronary artery disease (CAD) patients. VEGF was measured in 94 CAD patients' serum before revascularization, 1-month and 1-year after. Independently of clinical presentation, patients had lower VEGF concentration than a cohort of healthy subjects (median, IQ: 15.9, 9.0-264 pg/mL versus 419, 212-758 pg/mL; P < 0.001) at baseline. VEGF increased to 1-month (median, IQ: 276, 167-498 pg/mL; P < 0.001) and remained steady to 1-year (median, IQ: 320, 173-497 pg/mL; P < 0.001) approaching control levels. Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05). Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up. Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.

Original language	English
Article number	135357
Journal	Disease Markers
Volume	135357
Issue number	NA
DOIs	https://doi.org/10.1155/2014/135357
Publication status	Published - 2014

Access to Document

10.1155/2014/135357

DM2014-135357.pdfFinal published version, 574 KBLicence: CC BY-NC-ND

Cite this

@article{e006894b438948f0a963bc108beb5d3e,

title = "Prognostic Value of VEGF in Patients Submitted to Percutaneous Coronary Intervention",

abstract = "We examined the longitudinal changes of VEGF levels after percutaneous coronary intervention for predicting major adverse cardiac events (MACE) in coronary artery disease (CAD) patients. VEGF was measured in 94 CAD patients' serum before revascularization, 1-month and 1-year after. Independently of clinical presentation, patients had lower VEGF concentration than a cohort of healthy subjects (median, IQ: 15.9, 9.0-264 pg/mL versus 419, 212-758 pg/mL; P < 0.001) at baseline. VEGF increased to 1-month (median, IQ: 276, 167-498 pg/mL; P < 0.001) and remained steady to 1-year (median, IQ: 320, 173-497 pg/mL; P < 0.001) approaching control levels. Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05). Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up. Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.",

keywords = "MOLECULAR-MECHANISMS, SERUM-LEVELS, VASCULAR-PERMEABILITY, MOBILIZATION, ENDOTHELIAL-GROWTH-FACTOR, ANGIOGENESIS, DYSFUNCTION, ARTERY-DISEASE, FACTOR-A, CLINICAL-APPLICATIONS",

author = "C. Ramos and Patr{\'i}cia Napole{\~a}o and Mafalda Selas and Cl{\'a}udia Freixo and Viegas-Crespo, {Ana Maria} and Carmo, {Miguel Mota} and Ferreira, {Rui Cruz} and Teresa Pinheiro",

note = "info:eu-repo/grantAgreement/FCT/5646-ICCMS/82734/PT# The authors gratefully acknowledge the assistance of the staff of Servico de Cardiologia, Hospital de Santa Marta, and Ms. Rute Pinheiro for the help with laboratory work. The study was financially supported by Fundacao para a Ciencia e Tecnologia, PIC/IC/82734/2007 Contract and SFRM/BPD/6308/2009 Grant, and by Liga dos Amigos do Hospital de Santa Marta.",

year = "2014",

doi = "10.1155/2014/135357",

language = "English",

volume = "135357",

journal = "Disease Markers",

issn = "0278-0240",

publisher = "IOS Press",

number = "NA",

}

TY - JOUR

T1 - Prognostic Value of VEGF in Patients Submitted to Percutaneous Coronary Intervention

AU - Ramos, C.

AU - Napoleão, Patrícia

AU - Selas, Mafalda

AU - Freixo, Cláudia

AU - Viegas-Crespo, Ana Maria

AU - Carmo, Miguel Mota

AU - Ferreira, Rui Cruz

AU - Pinheiro, Teresa

N1 - info:eu-repo/grantAgreement/FCT/5646-ICCMS/82734/PT# The authors gratefully acknowledge the assistance of the staff of Servico de Cardiologia, Hospital de Santa Marta, and Ms. Rute Pinheiro for the help with laboratory work. The study was financially supported by Fundacao para a Ciencia e Tecnologia, PIC/IC/82734/2007 Contract and SFRM/BPD/6308/2009 Grant, and by Liga dos Amigos do Hospital de Santa Marta.

PY - 2014

Y1 - 2014

N2 - We examined the longitudinal changes of VEGF levels after percutaneous coronary intervention for predicting major adverse cardiac events (MACE) in coronary artery disease (CAD) patients. VEGF was measured in 94 CAD patients' serum before revascularization, 1-month and 1-year after. Independently of clinical presentation, patients had lower VEGF concentration than a cohort of healthy subjects (median, IQ: 15.9, 9.0-264 pg/mL versus 419, 212-758 pg/mL; P < 0.001) at baseline. VEGF increased to 1-month (median, IQ: 276, 167-498 pg/mL; P < 0.001) and remained steady to 1-year (median, IQ: 320, 173-497 pg/mL; P < 0.001) approaching control levels. Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05). Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up. Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.

AB - We examined the longitudinal changes of VEGF levels after percutaneous coronary intervention for predicting major adverse cardiac events (MACE) in coronary artery disease (CAD) patients. VEGF was measured in 94 CAD patients' serum before revascularization, 1-month and 1-year after. Independently of clinical presentation, patients had lower VEGF concentration than a cohort of healthy subjects (median, IQ: 15.9, 9.0-264 pg/mL versus 419, 212-758 pg/mL; P < 0.001) at baseline. VEGF increased to 1-month (median, IQ: 276, 167-498 pg/mL; P < 0.001) and remained steady to 1-year (median, IQ: 320, 173-497 pg/mL; P < 0.001) approaching control levels. Drug eluting stent apposition and previous medication intake produced a less steep VEGF evolution after intervention (P < 0.05). Baseline VEGF concentration <40.8 pg/mL conveyed increased risk for MACE in a 5-year follow-up. Results reflect a positive role of VEGF in recovery and support its importance in CAD prognosis.

KW - MOLECULAR-MECHANISMS

KW - SERUM-LEVELS

KW - VASCULAR-PERMEABILITY

KW - MOBILIZATION

KW - ENDOTHELIAL-GROWTH-FACTOR

KW - ANGIOGENESIS

KW - DYSFUNCTION

KW - ARTERY-DISEASE

KW - FACTOR-A

KW - CLINICAL-APPLICATIONS

U2 - 10.1155/2014/135357

DO - 10.1155/2014/135357

M3 - Article

C2 - 25110384

SN - 0278-0240

VL - 135357

JO - Disease Markers

JF - Disease Markers

IS - NA

M1 - 135357

ER -

Prognostic Value of VEGF in Patients Submitted to Percutaneous Coronary Intervention

Abstract

Access to Document

Fingerprint

Cite this